title: Patient concerns about human papillomavirus testing and 5-year intervals in routine cervical cancer screening.
abstract: OBJECTIVE
  To explore attitudes toward new cervical cancer screening options and understand factors associated with those beliefs among women in routine gynecologic care.
  
  
  METHODS
  We used an interviewer-administered survey of 551 women aged 36-62 years enrolled in the HPV in Perimenopause Study. Poisson regression with robust error variance was used to estimate prevalence ratios and 95% confidence intervals (CIs) to compare women's preferences for cervical cancer screening methods and frequency.
  
  
  RESULTS
  A majority of women (55.6%, 95% CI 51.4-59.8%) were aware that screening recommendations had changed, yet 74.1% (95% CI 70.3-77.7%) still believed women should be screened annually. If recommended by their doctor, 68.4% (95% CI 64.4-72.2%) were willing to extend screening to every 3 years, but only 25.2% (95% CI 21.9-29.2%) would extend screening to 5 years. Most women (60.7%, 95% CI 56.5-65.7%) expressed a strong preference for Pap testing, and 41.4% (95% CI 37.4-45.6%) expressed at least moderate concern over having a human papillomavirus (HPV) test without a Pap test. A desire for more frequent care, higher degree of worry and perceived risk, and abnormal screening history were all associated with reduced willingness to accept HPV testing and longer screening intervals.
  
  
  CONCLUSIONS
  A majority of routinely screened women indicated a willingness to adopt a cervical cancer screening strategy of cytology alone or Pap-HPV cotesting every 3 years if recommended by their physician. However, they remain concerned about HPV testing and extension of screening intervals to once every 5 years. Our results suggest continued reticence to accepting newer HPV-based screening algorithms among routinely screened women older than age 35 years.
authors.affiliation: Departments of Epidemiology, Gynecology and Obstetrics, and Pediatrics and the Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland; and the Department of Pathology, University of New Mexico School of Medicine, Albuquerque, New Mexico.
authors.forename: Michelle I
authors.initials: MI
authors.lastname: Silver
authors.forename: Anne F
authors.initials: AF
authors.lastname: Rositch
authors.forename: Anne E
authors.initials: AE
authors.lastname: Burke
authors.forename: Katie
authors.initials: K
authors.lastname: Chang
authors.forename: Raphael
authors.initials: R
authors.lastname: Viscidi
authors.forename: Patti E
authors.initials: PE
authors.lastname: Gravitt
mesh_terms: D000328:Adult; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008403:Mass Screening / Q000523:psychology* / Q000592:standards; D008875:Middle Aged; D030361:Papillomavirus Infections / Q000175:diagnosis*; D010342:Patient Acceptance of Health Care; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis*